DUBLIN–(BUSINESS WIRE)–The “Global
Krabbe Disease Treatment Market 2018-2022” report has been
added to ResearchAndMarkets.com’s offering.
Global krabbe disease treatment market to grow at a CAGR of 7.24% during
the period 2018-2022.
The report has been prepared based on an in-depth market analysis with
inputs from industry experts. The report covers the market landscape and
its growth prospects over the coming years. The report also includes a
discussion of the key vendors operating in this market.
One trend in the market is emergence of pharmacological chaperone
therapy. More than two-fifth known cases of Krabbe disease are due to
missense mutation in the GLC enzyme. Such mutations result in the
disruption of enzyme folding and ultimately stops the GLC from reaching
its site of action in enough amounts in the lysosome.
According to the report, one driver in the market is special drug
designation. An important factor that is expected to drive market growth
is the assignment of special drug designations to drugs and biologics
that are intended for the safe and effective treatment of Krabbe
disease. The priority review program for facilitating fast drug
approvals is offered by the Food and Drug Administration (FDA).
Further, the report states that one challenge in the market is limited
patient pool for clinical trials.
- Johnson & Johnson
Key Topics Covered:
Part 01: Executive Summary
Part 02: Scope of the Report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Market Landscape
Part 06: Market Sizing
Part 07: Five Forces Analysis
Part 08: Pipeline Analysis
Part 09: Market Segmentation by Therapy
Part 10: Customer Landscape
Part 11: Regional Landscape
Part 12: Decision Framework
Part 13: Drivers and Challenges
Part 14: Market Trends
Part 15: Vendor Landscape
Part 16: Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/c95tm4/global_krabbe?w=4
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Nervous System Drugs, Endocrine
and Metabolic Disorders Drugs